Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetrelimab + JNJ-86974680 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cetrelimab | JNJ63723283|JNJ 63723283|JNJ-63723283 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 122 | Cetrelimab (JNJ-63723283) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 28943093). | |
JNJ-86974680 | JNJ 86974680|JNJ86974680 | Limited information is currently available on JNJ-86974680 (Nov 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06116786 | Phase I | Cetrelimab + JNJ-86974680 | A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer | Recruiting | USA | ESP | DEU | 1 |